Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
SRPT Sarepta Therapeutics PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: SRPT
- PE Ratio
The current PE ratio of SRPT can't be determined, as the TTM EPS of -$2.51 is negative. The last PE ratio of Sarepta Therapeutics, recorded in December 2024, was 49.23.
SRPT PE ratio history
How has SRPT's PE ratio performed in the past
Today
N/A
Average
N/A
Median
N/A
Minimum
N/A
Maximum
N/A
Sarepta Therapeutics PE ratio by year
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | 49.23 | N/A | $121.59 | $2.47 |
| 2023 | N/A | N/A | $96.43 | -$5.8 |
| 2022 | N/A | N/A | $129.58 | -$8.03 |
| 2021 | N/A | N/A | $90.05 | -$5.15 |
| 2020 | N/A | N/A | $170.49 | -$7.11 |
| 2019 | N/A | N/A | $129.04 | -$9.71 |
| 2018 | N/A | N/A | $109.13 | -$5.46 |
| 2017 | N/A | N/A | $55.64 | -$0.86 |
| 2016 | N/A | N/A | $27.43 | -$5.49 |
| 2015 | N/A | N/A | $38.58 | -$5.2 |
| 2014 | N/A | N/A | $14.47 | -$3.39 |
| 2013 | N/A | N/A | $20.37 | -$3.31 |
| 2012 | N/A | N/A | $25.8 | -$5.14 |
| 2011 | N/A | N/A | $4.47 | -$0.11 |
| 2010 | N/A | N/A | $12.72 | -$1.74 |
Sarepta Therapeutics PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2025 | N/A | N/A | $63.82 | -$2.51 |
| Dec 2024 | 49.23 | -38.51% | $121.59 | $2.47 |
| Sep 2024 | 80.06 | -62% | $124.89 | $1.56 |
| Jun 2024 | 210.67 | -33.28% | $158 | $0.75 |
| Mar 2024 | 315.76 | N/A | $129.46 | $0.41 |
| Dec 2023 | N/A | N/A | $96.43 | -$5.8 |
| Sep 2023 | N/A | N/A | $121.22 | -$7.83 |
| Jun 2023 | N/A | N/A | $114.52 | -$10.31 |
| Mar 2023 | N/A | N/A | $137.83 | -$12.69 |
| Dec 2022 | N/A | N/A | $129.58 | -$8.03 |
| Sep 2022 | N/A | N/A | $110.54 | -$8.22 |
| Jun 2022 | N/A | N/A | $74.96 | -$5.88 |
| Mar 2022 | N/A | N/A | $78.12 | -$4.25 |
| Dec 2021 | N/A | N/A | $90.05 | -$5.15 |
| Sep 2021 | N/A | N/A | $92.48 | -$6.13 |
SRPT Price vs fair value
How does SRPT's price compare to its estimated fair value based on its growth
SRPT average PE ratio chart
What is the average PE ratio of SRPT for the past years
3-year avg
N/A
5-year avg
N/A
10-year avg
N/A
15-year avg
N/A
SRPT PE vs peers
What is SRPT's PE ratio compared to its peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| NVAX Novavax Inc | 2.36 | $1.16B |
| PTCT Ptc Therapeutics Inc | 6.76 | $4.05B |
| GILD Gilead Sciences Inc | 22.86 | $135.61B |
| BCRX Biocryst Pharmaceuticals Inc | N/A | $2.31B |
| ALNY Alnylam Pharmaceuticals Inc | N/A | $39.81B |
| RNA Avidity Biosciences Inc | N/A | $4.12B |
| INSM INSMED Inc | N/A | $13.42B |
| SRPT Sarepta Therapeutics Inc | N/A | $3.89B |
Frequently asked questions
What is Sarepta Therapeutics's PE ratio?
The current price to earnings ratio of SRPT can't be calculated, as its EPS of -$2.51 is negative.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.